IEM Seminar Series: Fighting cancer with bioengineered nanomaterials
Event details
| Date | 15.07.2024 |
| Hour | 13:30 › 14:30 |
| Speaker | Prof. Andy Tay, Department of Biomedical Engineering, National University of Singapore |
| Location | |
| Category | Conferences - Seminars |
| Event Language | English |
Abstract
Chimeric Antigen Receptor T cell (CAR-T) therapy is a breakthrough medicine that has revolutionized how cancer is treated. Nevertheless, CAR-T cell manufacturing faces challenges such as poor cell quality and low yield of transfected cells. Here, I will share a high throughput nano-scale method (NExT) to transfect diverse allogenic immune cells with high efficiency.
Despite its promise, clinical translation of nanomedicine has been limited attributing to reasons such as complex cancer microenvironment and low throughput of screening models. In the second half of my talk, I will share how our projects on multifunctional lipid nanoparticles for synergistic chemo-immuno-metabolic anti-cancer therapy and a DNA barcoded gold nanoparticle library for efficient in vivo screening.
Biography
Andy Tay graduated in 2014 from NUS with a First-Class Honors in Biomedical Engineering. He later headed to the University of California, Los Angeles for his PhD studies and graduated in 2017 as the recipient of the Harry M Showman Commencement Award. Andy next received his postdoctoral training at Stanford University before heading to Imperial College London as an 1851 Royal Commission Brunel Research Fellow. He is currently a Presidential Young Professor in NUS.
Andy is a recipient of international awards including the Interstellar Initiative Early-Career Faculty Award, Christopher Hewitt Outstanding Young Investigator Award, Terasaki Young Innovator Award. He is listed as a 2019 Forbes 30 Under 30 (US/Canada, Science), 2020 World Economic Forum Young Scientist and 2022/3 Top 2% Scientist in the World by Stanford University.
Chimeric Antigen Receptor T cell (CAR-T) therapy is a breakthrough medicine that has revolutionized how cancer is treated. Nevertheless, CAR-T cell manufacturing faces challenges such as poor cell quality and low yield of transfected cells. Here, I will share a high throughput nano-scale method (NExT) to transfect diverse allogenic immune cells with high efficiency.
Despite its promise, clinical translation of nanomedicine has been limited attributing to reasons such as complex cancer microenvironment and low throughput of screening models. In the second half of my talk, I will share how our projects on multifunctional lipid nanoparticles for synergistic chemo-immuno-metabolic anti-cancer therapy and a DNA barcoded gold nanoparticle library for efficient in vivo screening.
Biography
Andy Tay graduated in 2014 from NUS with a First-Class Honors in Biomedical Engineering. He later headed to the University of California, Los Angeles for his PhD studies and graduated in 2017 as the recipient of the Harry M Showman Commencement Award. Andy next received his postdoctoral training at Stanford University before heading to Imperial College London as an 1851 Royal Commission Brunel Research Fellow. He is currently a Presidential Young Professor in NUS.
Andy is a recipient of international awards including the Interstellar Initiative Early-Career Faculty Award, Christopher Hewitt Outstanding Young Investigator Award, Terasaki Young Innovator Award. He is listed as a 2019 Forbes 30 Under 30 (US/Canada, Science), 2020 World Economic Forum Young Scientist and 2022/3 Top 2% Scientist in the World by Stanford University.
Practical information
- General public
- Free